MX2021012710A - Glicoproteinas sialiladas. - Google Patents

Glicoproteinas sialiladas.

Info

Publication number
MX2021012710A
MX2021012710A MX2021012710A MX2021012710A MX2021012710A MX 2021012710 A MX2021012710 A MX 2021012710A MX 2021012710 A MX2021012710 A MX 2021012710A MX 2021012710 A MX2021012710 A MX 2021012710A MX 2021012710 A MX2021012710 A MX 2021012710A
Authority
MX
Mexico
Prior art keywords
shear stress
stable
sialylated glycoproteins
pharmaceutical
preparations
Prior art date
Application number
MX2021012710A
Other languages
English (en)
Inventor
Siddhesh D Patil
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of MX2021012710A publication Critical patent/MX2021012710A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Se describen preparaciones farmacéuticas que contienen inmunoglobulinas hipersialiladas, las preparaciones son estables al esfuerzo de cizalla; las composiciones farmacéuticas descritas en la presente descripción proporcionan composiciones de hsIgG farmacéuticamente aceptables que son estables contra el esfuerzo de cizalla (p. ej., no se forman un número significativo de partículas subvisibles cuando la formulación se somete a esfuerzo de cizalla, tal como agitación, por ejemplo, durante el envío) y, por lo tanto, pueden enviarse y manipularse en forma líquida.
MX2021012710A 2019-04-18 2020-04-17 Glicoproteinas sialiladas. MX2021012710A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962836016P 2019-04-18 2019-04-18
PCT/US2020/028863 WO2020215021A1 (en) 2019-04-18 2020-04-17 Sialylated glycoproteins

Publications (1)

Publication Number Publication Date
MX2021012710A true MX2021012710A (es) 2021-11-12

Family

ID=72837963

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012710A MX2021012710A (es) 2019-04-18 2020-04-17 Glicoproteinas sialiladas.

Country Status (20)

Country Link
US (1) US20220211849A1 (es)
EP (1) EP3955962A4 (es)
JP (1) JP2022529168A (es)
KR (1) KR20220002963A (es)
CN (1) CN113795275A (es)
AU (1) AU2020259492A1 (es)
BR (1) BR112021020509A8 (es)
CA (1) CA3137101A1 (es)
CL (1) CL2021002668A1 (es)
CO (1) CO2021013926A2 (es)
CR (1) CR20210521A (es)
EA (1) EA202192860A1 (es)
EC (1) ECSP21078309A (es)
IL (1) IL287306A (es)
JO (1) JOP20210281A1 (es)
MX (1) MX2021012710A (es)
PE (1) PE20220383A1 (es)
SG (1) SG11202110942SA (es)
WO (1) WO2020215021A1 (es)
ZA (1) ZA202109184B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113474360A (zh) 2019-02-18 2021-10-01 伊莱利利公司 治疗性抗体制剂
JP2023551190A (ja) 2020-11-20 2023-12-07 モメンタ ファーマシューティカルズ インコーポレイテッド シアリル化糖タンパク質
US11735303B2 (en) * 2021-06-22 2023-08-22 David Haase Apparatus and method for determining a composition of a replacement therapy treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1832756A (zh) * 2003-06-09 2006-09-13 约翰·A·麦金太尔 通过氧化还原反应改变血浆蛋白质结合专一性的方法
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
EA014513B1 (ru) * 2005-08-03 2010-12-30 Иммьюноджен, Инк. Композиция иммуноконъюгата
SG176256A1 (en) * 2009-05-27 2012-01-30 Baxter Int A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
FR2961107B1 (fr) * 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
US20150252108A1 (en) * 2012-09-26 2015-09-10 Momenta Pharmaceuticals, Inc. Glycoprotein preparations
WO2014179601A2 (en) * 2013-05-02 2014-11-06 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
JP6594860B2 (ja) * 2013-05-29 2019-10-23 エフ．ホフマン−ラ ロシュ アーゲー シアル酸付加の定量的調節
EP3569224B1 (en) * 2017-01-11 2022-12-14 Celltrion Inc. Stable liquid formula

Also Published As

Publication number Publication date
BR112021020509A2 (pt) 2022-03-15
BR112021020509A8 (pt) 2023-01-10
ZA202109184B (en) 2023-04-26
CN113795275A (zh) 2021-12-14
EP3955962A1 (en) 2022-02-23
EP3955962A4 (en) 2022-12-14
SG11202110942SA (en) 2021-11-29
US20220211849A1 (en) 2022-07-07
ECSP21078309A (es) 2021-11-30
JP2022529168A (ja) 2022-06-17
IL287306A (en) 2021-12-01
CO2021013926A2 (es) 2021-10-29
CL2021002668A1 (es) 2022-05-27
PE20220383A1 (es) 2022-03-18
JOP20210281A1 (ar) 2023-01-30
WO2020215021A1 (en) 2020-10-22
AU2020259492A1 (en) 2021-11-11
KR20220002963A (ko) 2022-01-07
CA3137101A1 (en) 2020-10-22
CR20210521A (es) 2022-04-01
EA202192860A1 (ru) 2021-12-23

Similar Documents

Publication Publication Date Title
JOP20210281A1 (ar) بروتينات سكرية محمضة بالسَّيَاليك
WO2016138030A3 (en) Compositions and methods for tolerizing the immune system to allergens
MX2017012878A (es) Composiciones gomosas de multicomponentes con nucleo duro.
MX335944B (es) Composiciones que comprenden sulfato de salbutamol.
US8937102B2 (en) Fluid cocamide monoethanolamide concentrates and methods of preparation
MX2020002850A (es) Metodos para reducir la formacion de particulas y composiciones formadas a partir de estas.
EP4400098A3 (en) Co-amorphous forms of beta-lactoglobulin and a drug substance
SG10201802129QA (en) A pharmaceutical composition for neuropathic pain
MX2020007760A (es) Composiciones y metodos para mejorar la biodisponibilidad de 5-hidroxitriptofano.
BR112015019580A2 (pt) processo para preparar uma solução aquosa, solução aquosa, medicamento, alimento, ingrediente de alimento ou suplemento alimentício e método para reduzir a assimilação calórica
WO2019031898A3 (ko) 약학 조성물 및 이의 제조방법
MX2021004551A (es) Composicion farmaceutica para el tratamiento de la anemia aplasica.
PH12020551798A1 (en) Improved pharmaceutical formulations
SG10201807034XA (en) A pharmaceutical composition for improving or preventing progression of Chronic Kidney Disease
BR112017019753A2 (pt) uso de composições de astaxantina, composição, processo para preparação de um produto alimentício ou ração, e, preparação medicinal
MX2019013053A (es) Composicion que contiene ciclodextrina y busulfan.
GB850006A (en) Improvements in or relating to derivatives of nitrofuran
MX2022015232A (es) Composicion farmaceutica acuosa de levilimab y su uso.
WO2016175589A3 (ko) 혼합 생약 추출물을 함유하는 호흡기 질환 예방 또는 치료용 약학적 조성물
PH12020551547A1 (en) Pharmaceutical preparation
EP4417257A3 (en) Pharmaceutical composition, package and method for producing the same
MX2017013265A (es) Composicion para formulacion cosmetica humectante de larga duracion que comprende manteca de ucuuba con altas concentraciones de acido miristico asi como el uso de la formulacion para la preparacion de un producto cosmetico altamente humectante y kit.
KR101779676B1 (ko) 균일한 혼합도의 투석액 조제용 조성물의 제조방법
MX2022006601A (es) Composicion espesante de alimento y metodo.
SA520420369B1 (ar) تركيبة مسحوق جاف صيدلانية للاستنشاق تشتمل على هرمون درقي